Integrated BioPharma Inc (INBP)

Name: Integrated BioPharma Inc Financial Statements
Creator: Quarter Results

Consumer Defensive | Packaged Foods

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$11.3M

Net Income

-$762K

Operating Margin

-8.1%

Free Cash Flow

$1.9M

Debt / Assets

18.4%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Integrated BioPharma Inc (INBP).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-03-31	2024-12-31
Revenue	11,280,000	12,689,000	13,947,000	12,614,000
Cost of Revenue	11,251,000	11,670,000	12,396,000	11,443,000
Gross Profit	29,000	1,019,000	1,551,000	1,171,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	943,000	856,000	812,000	969,000
Operating Expenses	943,000	856,000	812,000	969,000
Operating Income	-914,000	163,000	739,000	202,000
Interest Expense	0	0	0	0
Income Before Tax	-874,000	196,000	778,000	185,000
Income Tax Expense	-112,000	73,000	167,000	69,000
Net Income	-762,000	123,000	611,000	116,000
Per Share
EPS	-0.02	0.00	0.02	0.00
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Integrated BioPharma Inc (INBP).
Income Statement (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-09-30	2022-06-30
Revenue	54,353,000	50,317,000	50,672,000	0	56,246,000
Cost of Revenue	48,791,000	46,433,000	46,611,000	0	49,694,000
Gross Profit	5,562,000	3,884,000	4,061,000	0	6,552,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	3,542,000	3,633,000	3,941,000	0	3,807,000
Operating Expenses	3,542,000	3,633,000	3,941,000	0	3,807,000
Operating Income	2,020,000	251,000	120,000	0	1,966,000
Interest Expense	46,000	0	40,000	0	107,000
Income Before Tax	2,062,000	268,000	100,000	0	2,597,000
Income Tax Expense	1,254,000	156,000	134,000	0	-1,241,000
Net Income	808,000	112,000	-34,000	0	3,838,000
Per Share
EPS	0.03	0.00	0.00	0.00	0.13
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Integrated BioPharma Inc (INBP).
Balance Sheet (Quarterly)	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Assets
Cash and Cash Equivalents	3,615,000	1,677,000	1,316,000	331,000
Short Term Investments	0	0	0	12,000
Net Receivables	5,430,000	4,668,000	4,511,000	4,888,000
Inventory	9,362,000	11,244,000	10,261,000	11,055,000
Total Current Assets	18,763,000	17,875,000	16,372,000	16,626,000
Property Plant Equipment	2,749,000	3,675,000	4,276,000	3,777,000
Goodwill and Intangibles	0	0	0	0
Total Assets	24,901,000	26,207,000	25,431,000	25,250,000
Liabilities
Account Payables	2,267,000	2,510,000	2,266,000	3,209,000
Short Term Debt	1,358,000	1,904,000	1,860,000	643,000
Total Current Liabilities	4,248,000	6,123,000	4,828,000	5,263,000
Long Term Debt	336,000	846,000	1,742,000	1,412,000
Total Liabilities	4,584,000	6,969,000	6,570,000	6,675,000
Shareholders Equity
Retained Earnings	-31,419,000	-32,227,000	-32,339,000	-32,305,000
Total Shareholders Equity	20,317,000	19,238,000	18,861,000	18,575,000

Balance sheet annual history for Integrated BioPharma Inc (INBP).
Balance Sheet (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Assets
Cash and Cash Equivalents	3,615,000	1,677,000	1,316,000	331,000	210,000
Short Term Investments	0	0	0	12,000	0
Net Receivables	5,430,000	4,668,000	4,511,000	4,888,000	5,776,000
Inventory	9,362,000	11,244,000	10,261,000	11,055,000	11,695,000
Total Current Assets	18,763,000	17,875,000	16,372,000	16,626,000	17,998,000
Property Plant Equipment	2,749,000	3,675,000	4,276,000	3,777,000	4,107,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	24,901,000	26,207,000	25,431,000	25,250,000	25,440,000
Liabilities
Account Payables	2,267,000	2,510,000	2,266,000	3,209,000	3,496,000
Short Term Debt	1,358,000	1,904,000	1,860,000	643,000	4,130,000
Total Current Liabilities	4,248,000	6,123,000	4,828,000	5,263,000	9,236,000
Long Term Debt	336,000	846,000	1,742,000	1,412,000	1,870,000
Total Liabilities	4,584,000	6,969,000	6,570,000	6,675,000	11,106,000
Shareholders Equity
Retained Earnings	-31,419,000	-32,227,000	-32,339,000	-32,305,000	-36,143,000
Total Shareholders Equity	20,317,000	19,238,000	18,861,000	18,575,000	14,334,000

Cash flow quarterly history for Integrated BioPharma Inc (INBP).
Cash Flow Statement (Quarterly)	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Operating Activities
Net Income	808,000	112,000	-34,000	3,838,000
Depreciation & Amortization	951,000	1,221,000	1,154,000	834,000
Stock Based Compensation	185,000	252,000	320,000	369,000
Change in Working Capital	-1,502,000	-744,000	-302,000	565,000
Operating Cash Flow	2,065,000	943,000	1,232,000	4,091,000
Investing Activities
Capital Expenditure	-191,000	-553,000	-116,000	-486,000
Investments	-191,000	-553,000	-116,000	-486,000
Investing Cash Flow	-205,000	-553,000	-111,000	-465,000
Financing Activities
Debt Repayment	-8,000	-42,000	-136,000	-58,157,000
Common Stock Issued/Repurchased	86,000	13,000	4,000	34,000
Dividends Paid	0	0	0	0
Financing Cash Flow	78,000	-29,000	-136,000	-3,505,000
Summary
Free Cash Flow	1,874,000	390,000	1,116,000	3,605,000
Net Change in Cash	1,938,000	361,000	985,000	121,000

Cash flow annual history for Integrated BioPharma Inc (INBP).
Cash Flow Statement (Annual)	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30
Operating Activities
Net Income	808,000	112,000	-34,000	3,838,000	8,013,000
Depreciation & Amortization	951,000	1,221,000	1,154,000	834,000	826,000
Stock Based Compensation	185,000	252,000	320,000	369,000	231,000
Change in Working Capital	-1,502,000	-744,000	-302,000	565,000	-3,046,000
Operating Cash Flow	2,065,000	943,000	1,232,000	4,091,000	3,050,000
Investing Activities
Capital Expenditure	-191,000	-553,000	-116,000	-486,000	-295,000
Investments	-191,000	-553,000	-116,000	-486,000	-295,000
Investing Cash Flow	-205,000	-553,000	-111,000	-465,000	-199,000
Financing Activities
Debt Repayment	-8,000	-42,000	-136,000	-58,157,000	-60,728,000
Common Stock Issued/Repurchased	86,000	13,000	4,000	34,000	0
Dividends Paid	0	0	0	0	0
Financing Cash Flow	78,000	-29,000	-136,000	-3,505,000	-3,043,000
Summary
Free Cash Flow	1,874,000	390,000	1,116,000	3,605,000	2,755,000
Net Change in Cash	1,938,000	361,000	985,000	121,000	-192,000